{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:22:28Z","timestamp":1789662148994,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ygyno.2022.01.032","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:13:13Z","timestamp":1644279193000},"page":"49-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers"],"prefix":"10.1016","volume":"165","author":[{"given":"Matthew K.","family":"Wagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P.","family":"Mojdehbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Godecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel W.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.01.032_bb0005","author":"Society"},{"issue":"12","key":"10.1016\/j.ygyno.2022.01.032_bb0010","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.032_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.01.032_bb0020","first-page":"380","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines","volume":"18","author":"Daly","year":"2020","journal-title":"JNCCN"},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.032_bb0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ygyno.2017.10.034","article-title":"Disparities in genetics assessment for women with ovarian cancer: can we do better?","volume":"149","author":"Manrriquez","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2022.01.032_bb0030","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","article-title":"Family history of breast or ovarian cancer","volume":"293","author":"Armstrong","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2022.01.032_bb0035","article-title":"Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center","author":"Chapman-Davis","year":"2020","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.032_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2013.12.039","article-title":"Gynecologic cancer disparities: a report from the health disparities taskforce of the society of gynecologic oncology","volume":"133","author":"Collins","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.032_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-020-01382-0","article-title":"Movement of poly-ADP ribose (PARP) inhibition into frontline treatment of ovarian cancer","author":"Onstad","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.032_bb0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.19.01304","article-title":"Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant","volume":"38","author":"Litton","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2022.01.032_bb0055","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ygyno.2022.01.032_bb0065","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ygyno.2022.01.032_bb0070","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/AOG.0000000000000643","article-title":"Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines","volume":"125","author":"Bristow","year":"2015","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.032_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2017.12.006","article-title":"Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies","volume":"149","author":"Rauh-Hain","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.032_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.22797","article-title":"Racial disparities in blacks with gynecologic cancers","volume":"110","author":"Farley","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.032_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.032_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2020.01.040","article-title":"Are ethnic and racial minority women less likely to participate in clinical trials?","volume":"157","author":"Patel","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.032_bb0095","series-title":"Underrepresented Populations: a Systematic Review","first-page":"169","volume":"39","author":"Heller","year":"2019"},{"issue":"9","key":"10.1016\/j.ygyno.2022.01.032_bb0100","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.32755","article-title":"Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials","volume":"126","author":"Niranjan","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.032_bb0105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2015.05.014","article-title":"Minority participation in gynecologic oncology group (GOG) studies","volume":"138","author":"Scalici","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2022.01.032_bb0110","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.30621","article-title":"Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors","volume":"123","author":"Cragun","year":"2018","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:40Z","timestamp":1758772840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0090825822000713"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.032","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}